MSG07: An International Cohort Study Comparing Epidemiology and Outcomes of Patients With Cryptococcus neoformans or Cryptococcus gattii Infections.
Cryptococcus gattii
Cryptococcus neoformans
cryptococcosis
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
05 10 2021
05 10 2021
Historique:
received:
01
09
2020
accepted:
24
03
2021
pubmed:
28
3
2021
medline:
21
10
2021
entrez:
27
3
2021
Statut:
ppublish
Résumé
Cryptococcosis due to Cryptococcus neoformans and Cryptococcus gattii varies with geographic region, populations affected, disease manifestations, and severity of infection, which impact treatment. We developed a retrospective cohort of patients diagnosed with culture-proven cryptococcosis during 1995-2013 from 5 centers in North America and Australia. We compared underlying diseases, clinical manifestations, treatment, and outcomes in patients with C. gattii or C. neoformans infection. A total of 709 patients (452 C. neoformans; 257 C. gattii) were identified. Mean age was 50.2 years; 61.4% were male; and 52.3% were white. Time to diagnosis was prolonged in C. gattii patients compared with C. neoformans (mean, 52.2 vs 36.0 days; P < .003), and there was a higher proportion of C. gattii patients without underlying disease (40.5% vs 10.2%; P < .0001). Overall, 59% had central nervous system (CNS) infection, with lung (42.5%) and blood (24.5%) being common sites. Pulmonary infection was more common in patients with C. gattii than in those with C. neoformans (60.7% vs 32.1%; P < .0001). CNS or blood infections were more common in C. neoformans-infected patients (P ≤ .0001 for both). Treatment of CNS disease with induction therapy of amphotericin B and flucytosine occurred in 76.4% of patients. Crude 12-month mortality was higher in patients with C. neoformans (28.4% vs 20.2%; odds ratio, 1.56 [95% confidence interval, 1.08-2.26]). This study emphasizes differences in species-specific epidemiology and outcomes of patients with cryptococcosis, including underlying diseases, site of infection, and mortality. Species identification in patients with cryptococcosis is necessary to discern epidemiologic patterns, guide treatment regimens, and predict clinical progression and outcomes.
Sections du résumé
BACKGROUND
Cryptococcosis due to Cryptococcus neoformans and Cryptococcus gattii varies with geographic region, populations affected, disease manifestations, and severity of infection, which impact treatment.
METHODS
We developed a retrospective cohort of patients diagnosed with culture-proven cryptococcosis during 1995-2013 from 5 centers in North America and Australia. We compared underlying diseases, clinical manifestations, treatment, and outcomes in patients with C. gattii or C. neoformans infection.
RESULTS
A total of 709 patients (452 C. neoformans; 257 C. gattii) were identified. Mean age was 50.2 years; 61.4% were male; and 52.3% were white. Time to diagnosis was prolonged in C. gattii patients compared with C. neoformans (mean, 52.2 vs 36.0 days; P < .003), and there was a higher proportion of C. gattii patients without underlying disease (40.5% vs 10.2%; P < .0001). Overall, 59% had central nervous system (CNS) infection, with lung (42.5%) and blood (24.5%) being common sites. Pulmonary infection was more common in patients with C. gattii than in those with C. neoformans (60.7% vs 32.1%; P < .0001). CNS or blood infections were more common in C. neoformans-infected patients (P ≤ .0001 for both). Treatment of CNS disease with induction therapy of amphotericin B and flucytosine occurred in 76.4% of patients. Crude 12-month mortality was higher in patients with C. neoformans (28.4% vs 20.2%; odds ratio, 1.56 [95% confidence interval, 1.08-2.26]).
CONCLUSIONS
This study emphasizes differences in species-specific epidemiology and outcomes of patients with cryptococcosis, including underlying diseases, site of infection, and mortality. Species identification in patients with cryptococcosis is necessary to discern epidemiologic patterns, guide treatment regimens, and predict clinical progression and outcomes.
Identifiants
pubmed: 33772538
pii: 6193427
doi: 10.1093/cid/ciab268
pmc: PMC8473583
mid: NIHMS1738781
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1133-1141Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI093257
Pays : United States
Organisme : Merck, Inc.
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
N Engl J Med. 1987 Aug 6;317(6):334-41
pubmed: 3299095
PLoS One. 2013;8(3):e60431
pubmed: 23555970
Emerg Infect Dis. 2008 Nov;14(11):1781-3
pubmed: 18976570
Clin Infect Dis. 2014 Mar;58(5):736-45
pubmed: 24319084
J Microbiol Immunol Infect. 2011 Oct;44(5):338-45
pubmed: 21524972
PLoS One. 2013 Sep 03;8(9):e74737
pubmed: 24019979
Clin Infect Dis. 2012 Sep;55(6):789-98
pubmed: 22670042
Lancet Infect Dis. 2015 Mar;15(3):348-55
pubmed: 25467646
AIDS. 2009 Jun 1;23(9):1182-3
pubmed: 19451796
Clin Infect Dis. 2015 May 1;60(9):1368-76
pubmed: 25632012
Clin Infect Dis. 2011 Dec;53(12):1188-95
pubmed: 22016503
Emerg Infect Dis. 2007 Jan;13(1):51-7
pubmed: 17370515
Emerg Infect Dis. 2011 Feb;17(2):193-9
pubmed: 21291588
BMC Microbiol. 2014 Dec 21;14:323
pubmed: 25528464
Clin Infect Dis. 1995 Jul;21(1):28-34; discussion 35-6
pubmed: 7578756
Clin Microbiol Rev. 2014 Oct;27(4):980-1024
pubmed: 25278580
Clin Infect Dis. 2009 Jun 15;48(12):1775-83
pubmed: 19441980
PLoS One. 2012;7(8):e43582
pubmed: 22937064
Mem Inst Oswaldo Cruz. 2011 Sep;106(6):725-30
pubmed: 22012227
Clin Infect Dis. 1995 Mar;20(3):611-6
pubmed: 7756484
Emerg Infect Dis. 2013 Oct;19(10):1620-6
pubmed: 24050410
Clin Infect Dis. 2013 Aug;57(4):543-51
pubmed: 23697747
Clin Infect Dis. 2010 Feb 1;50(3):291-322
pubmed: 20047480
Clin Infect Dis. 2000 Aug;31(2):499-508
pubmed: 10987712
Mycopathologia. 2012 Jun;173(5-6):311-9
pubmed: 21960040
Appl Environ Microbiol. 2007 Mar;73(5):1433-43
pubmed: 17194837
J Clin Microbiol. 2010 Feb;48(2):539-44
pubmed: 20007380
PLoS One. 2011;6(12):e28550
pubmed: 22163313
PLoS One. 2014 Feb 19;9(2):e88875
pubmed: 24586423
J Clin Microbiol. 1982 Mar;15(3):535-7
pubmed: 7042750
N Engl J Med. 2018 Mar 15;378(11):1004-1017
pubmed: 29539274
Emerg Infect Dis. 2010 Feb;16(2):251-7
pubmed: 20113555
Med Mycol. 2018 Feb 1;56(2):129-144
pubmed: 28525610
AIDS. 2009 Mar 27;23(6):701-6
pubmed: 19279443
Emerg Infect Dis. 2012 Jun;18(6):1012-5
pubmed: 22608164
Clin Infect Dis. 2018 Feb 1;66(4):608-611
pubmed: 29028978
mSphere. 2017 Jan 11;2(1):
pubmed: 28101535
AIDS. 2009 Feb 20;23(4):525-30
pubmed: 19182676